MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) will present seven research posters on Latuda® (lurasidone HCl) at the 169th Annual Meeting of the American Psychiatric Association (APA), which will be held May 14-18 in Atlanta, Georgia. LATUDA is an atypical antipsychotic indicated for the treatment of adult patients with major depressive episodes associated with bipolar I disorder (bipolar depression) both as monotherapy and as adjunctive therapy with lithium or valproate, and for the treatment of adult patients with schizophrenia.
